{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:49:56Z","timestamp":1791452996302,"version":"4.3.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01026-7","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:57:25Z","timestamp":1791449845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Insights from a Multi-Country Survey: Healthcare Providers\u2019 Perspectives on the Management of Adults with Neurofibromatosis Type 1 and Plexiform Neurofibroma"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6987-027X","authenticated-orcid":false,"given":"Ayo","family":"Adeyemi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie E.","family":"Ferner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4064-6079","authenticated-orcid":false,"given":"Phioanh L.","family":"Nghiemphu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6414-0647","authenticated-orcid":false,"given":"Susanna","family":"Burckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0656-3325","authenticated-orcid":false,"given":"Abby","family":"Crites","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Dettling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"1026_CR1","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13:834\u201343.","journal-title":"Lancet Neurol"},{"key":"1026_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13023-020-1310-3","volume":"15","author":"C Bergqvist","year":"2020","unstructured":"Bergqvist C, Servy A, Valeyrie-Allanore L, Ferkal S, Combemale P, Wolkenstein P. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020;15:37.","journal-title":"Orphanet J Rare Dis"},{"key":"1026_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/gim.2018.28","volume":"20","author":"DR Stewart","year":"2018","unstructured":"Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20:671\u201382.","journal-title":"Genet Med"},{"key":"1026_CR4","unstructured":"Friedman JM. Neurofibromatosis 1. In: Adam MP, Feldman J, Mirzaa GM, et al., eds. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle Copyright \u00a9 1993\u20132024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved."},{"key":"1026_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.spen.2006.01.005","volume":"13","author":"JH Tonsgard","year":"2006","unstructured":"Tonsgard JH. Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol. 2006;13:2\u20137.","journal-title":"Semin Pediatr Neurol"},{"key":"1026_CR6","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","volume":"34","author":"E Uusitalo","year":"2016","unstructured":"Uusitalo E, Rantanen M, Kallionp\u00e4\u00e4 RA, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016;34:1978\u201386.","journal-title":"J Clin Oncol"},{"key":"1026_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/bjc.2012.535","volume":"108","author":"OO Seminog","year":"2013","unstructured":"Seminog OO, Goldacre MJ. Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study. Br J Cancer. 2013;108:193\u20138.","journal-title":"Br J Cancer"},{"key":"1026_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/sj.bjc.6603227","volume":"95","author":"L Walker","year":"2006","unstructured":"Walker L, Thompson D, Easton D, et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer. 2006;95:233\u20138.","journal-title":"Br J Cancer"},{"key":"1026_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/neuonc\/nov200","volume":"18","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol. 2016;18:624\u201338.","journal-title":"Neuro Oncol"},{"key":"1026_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1477-7819-3-6","volume":"3","author":"RE Friedrich","year":"2005","unstructured":"Friedrich RE, Schmelzle R, Hartmann M, F\u00fcnsterer C, Mautner VF. Resection of small plexiform neurofibromas in neurofibromatosis type 1 children. World J Surg Oncol. 2005;3:6.","journal-title":"World J Surg Oncol"},{"key":"1026_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","volume":"160","author":"CE Prada","year":"2012","unstructured":"Prada CE, Rangwala FA, Martin LJ, et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr. 2012;160:461\u20137.","journal-title":"J Pediatr"},{"key":"1026_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ophtha.2016.09.020","volume":"124","author":"RA Avery","year":"2017","unstructured":"Avery RA, Katowitz JA, Fisher MJ, et al. Orbital\/periorbital plexiform neurofibromas in children with neurofibromatosis type 1: multidisciplinary recommendations for care. Ophthalmology. 2017;124:123\u201332.","journal-title":"Ophthalmology"},{"key":"1026_CR13","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","volume":"167A","author":"PL Wolters","year":"2015","unstructured":"Wolters PL, Burns KM, Martin S, et al. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life. Am J Med Genet A. 2015;167A:2103\u201313.","journal-title":"Am J Med Genet A"},{"key":"1026_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12883-023-03429-7","volume":"23","author":"HK Yoo","year":"2023","unstructured":"Yoo HK, Porteous A, Ng A, et al. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey. BMC Neurol. 2023;23:419.","journal-title":"BMC Neurol"},{"key":"1026_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1001\/archotol.131.8.712","volume":"131","author":"JB Wise","year":"2005","unstructured":"Wise JB, Cryer JE, Belasco JB, Jacobs I, Elden L. Management of head and neck plexiform neurofibromas in pediatric patients with neurofibromatosis type 1. Arch Otolaryngol Head Neck Surg. 2005;131:712\u20138.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"1026_CR16","first-page":"852","volume":"5","author":"A Agaimy","year":"2012","unstructured":"Agaimy A, Vassos N, Croner RS. Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen\u2019s disease): clinicopathological spectrum with pathogenetic considerations. Int J Clin Exp Pathol. 2012;5:852\u201362.","journal-title":"Int J Clin Exp Pathol"},{"key":"1026_CR17","volume":"38","author":"R Allen","year":"2021","unstructured":"Allen R, Epelman M, Cruz-Diaz O, Ellsworth P. Pelvic plexiform neurofibroma during bowel\/bladder dysfunction in an NF1 pediatric patient: a case report. Urol Case Rep. 2021;38:101722.","journal-title":"Urol Case Rep"},{"key":"1026_CR18","first-page":"i141","volume":"2","author":"G Hamoy-Jimenez","year":"2020","unstructured":"Hamoy-Jimenez G, Kim R, Suppiah S, Zadeh G, Bril V, Barnett C. Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neurooncol Adv. 2020;2:i141\u20139.","journal-title":"Neurooncol Adv"},{"key":"1026_CR19","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher MJ, Blakeley JO, Weiss BD, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24:1827\u201344.","journal-title":"Neuro Oncol"},{"key":"1026_CR20","first-page":"55","volume":"12","author":"C Copley-Merriman","year":"2021","unstructured":"Copley-Merriman C, Yang X, Juniper M, Amin S, Yoo HK, Sen SS. Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic literature review. Adolesc Health Med Ther. 2021;12:55\u201366.","journal-title":"Adolesc Health Med Ther"},{"key":"1026_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28138","volume":"67","author":"E Martin","year":"2020","unstructured":"Martin E, Coert JH, Flucke UE, et al. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: a nationwide cohort study. Pediatr Blood Cancer. 2020;67:e28138.","journal-title":"Pediatr Blood Cancer"},{"key":"1026_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1634\/theoncologist.2013-0328","volume":"19","author":"M Farid","year":"2014","unstructured":"Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19:193\u2013201.","journal-title":"Oncologist"},{"key":"1026_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s40120-025-00855-2","volume":"15","author":"X Yang","year":"2026","unstructured":"Yang X, Done N, Cunnington M, et al. Clinical and humanistic burden among adults with neurofibromatosis type 1 and symptomatic plexiform neurofibroma in the United States. Neurol Ther. 2026;15:597\u2013616.","journal-title":"Neurol Ther"},{"key":"1026_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf269","volume":"8","author":"M Mrugala","year":"2026","unstructured":"Mrugala M, Adeyemi A, Johns J, Yang X, Wolkenstein P. Disease burden and unmet needs in adults with neurofibromatosis type 1 and plexiform neurofibromas: a systematic literature review. Neuro-oncol Adv. 2026;8:vdaf269.","journal-title":"Neuro-oncol Adv"},{"key":"1026_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/PHMT.S362679","volume":"14","author":"HB Radtke","year":"2023","unstructured":"Radtke HB, Berger A, Skelton T, Goetsch WA. Neurofibromatosis type 1 (NF1): addressing the transition from pediatric to adult care. Pediatric Health Med Ther. 2023;14:19\u201332.","journal-title":"Pediatric Health Med Ther"},{"key":"1026_CR26","unstructured":"AstraZeneca. Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type 1. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/koselugo-approved-in-japan-for-paediatric-patients-with-plexiform-neurofibromas.html. Accessed 28 July 2026."},{"key":"1026_CR27","unstructured":"AstraZeneca. Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/koselugo-approved-in-china-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas.html. Accessed 28 July 2026."},{"key":"1026_CR28","unstructured":"AstraZeneca. Koselugo (selumetinib) approved in US for paediatric patients with neurofibromatosis type 1 plexiform neurofibromas. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/koselugo-selumetinib-approved-in-us-for-paediatric-patients-with-neurofibromatosis-type-1-plexiform-neurofibromas.html#. Accessed 28 July 2026."},{"key":"1026_CR29","unstructured":"AstraZeneca. Koselugo approved in the EU for children with neurofibromatosis type 1 and plexiform neurofibromas. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/koselugo-approved-in-the-eu-for-children-with-neurofibromatosis-type-1-and-plexiform-neurofibromas.html#. Accessed 28 July 2026."},{"key":"1026_CR30","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","volume":"405","author":"AP Chen","year":"2025","unstructured":"Chen AP, Coyne GO, Wolters PL, et al. Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, Phase 3 study. Lancet. 2025;405:2217\u201330.","journal-title":"Lancet"},{"key":"1026_CR31","unstructured":"Food and Drug Administration. FDA approves mirdametinib for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mirdametinib-adult-and-pediatric-patients-neurofibromatosis-type-1-who-have-symptomatic. Accessed 28 July 2026."},{"key":"1026_CR32","unstructured":"NF Network. Challenges in the transition from pediatric to adult healthcare faced by patients with neurofibromatosis type 1. https:\/\/www.ctf.org\/wp-content\/uploads\/2024\/04\/2024_Transition_of_Care_Roundtable_White_Paper_Jan2025_Final.pdf. Accessed 28 July 2026."},{"key":"1026_CR33","doi-asserted-by":"publisher","first-page":"1323176","DOI":"10.3389\/fonc.2024.1323176","volume":"14","author":"FA Bashiri","year":"2024","unstructured":"Bashiri FA, Hundallah K, Abukhaled M, et al. Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations. Front Oncol. 2024;14:1323176.","journal-title":"Front Oncol"},{"key":"1026_CR34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajmg.b.32612","volume":"177","author":"AB Rietman","year":"2018","unstructured":"Rietman AB, van der Vaart T, Plasschaert E, et al. Emotional and behavioral problems in children and adolescents with neurofibromatosis type 1. Am J Med Genet B Neuropsychiatr Genet. 2018;177:319\u201328.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"1026_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/jpepsy\/jsae006","volume":"49","author":"A Siegel","year":"2024","unstructured":"Siegel A, Lockridge R, Struemph KL, et al. Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study. J Pediatr Psychol. 2024;49:383\u201391.","journal-title":"J Pediatr Psychol"},{"key":"1026_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/01.bpo.0000217719.10728.39","volume":"26","author":"AH Crawford","year":"2006","unstructured":"Crawford AH, Schorry EK. Neurofibromatosis update. J Pediatr Orthop. 2006;26:413\u201323.","journal-title":"J Pediatr Orthop"},{"key":"1026_CR37","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/ajmg.a.35982","volume":"161A","author":"A Van Lierde","year":"2013","unstructured":"Van Lierde A, Menni F, Bedeschi MF, et al. Healthcare transition in patients with rare genetic disorders with and without developmental disability: neurofibromatosis 1 and Williams\u2013Beuren syndrome. Am J Med Genet A. 2013;161A:1666\u201374.","journal-title":"Am J Med Genet A"},{"key":"1026_CR38","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/pch\/12.9.785","volume":"12","author":"M Kaufman","year":"2007","unstructured":"Kaufman M, Pinzon J, Canadian Paediatric Society, Adolescent Health Committee. Transition to adult care for youth with special health care needs. Paediatr Child Health. 2007;12:785\u20138.","journal-title":"Paediatr Child Health"},{"key":"1026_CR39","doi-asserted-by":"publisher","first-page":"e20182587","DOI":"10.1542\/peds.2018-2587","volume":"142","author":"PH White","year":"2018","unstructured":"White PH, Cooley WC, Transitions Clinical Report Authoring Group, American Academy of Pediatrics, American Academy of Family Physicians, American College of Physicians. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics. 2018;142:e20182587.","journal-title":"Pediatrics"},{"key":"1026_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2007","unstructured":"Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44:81\u20138.","journal-title":"J Med Genet"},{"key":"1026_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101818","volume":"56","author":"C Carton","year":"2023","unstructured":"Carton C, Evans DG, Blanco I, et al. ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine. 2023;56:101818.","journal-title":"EClinicalMedicine"},{"key":"1026_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.hctj.2025.100108","volume":"3","author":"DV Murrell","year":"2025","unstructured":"Murrell DV, Enzler CJ, Bretz L, et al. The impact of insurance on adolescent transition to adult care. Health Care Transit. 2025;3:100108.","journal-title":"Health Care Transit"},{"key":"1026_CR43","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1177\/1049732316665344","volume":"27","author":"MM Hennink","year":"2017","unstructured":"Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017;27:591\u2013608.","journal-title":"Qual Health Res"},{"key":"1026_CR44","doi-asserted-by":"publisher","first-page":"205031211982968","DOI":"10.1177\/2050312119829680","volume":"7","author":"A Heaney","year":"2019","unstructured":"Heaney A, Wilburn J, Langmead S, et al. A qualitative study of the impact of plexiform neurofibromas on need fulfilment in adults with neurofibromatosis type 1. SAGE Open Med. 2019;7:2050312119829680.","journal-title":"SAGE Open Med"},{"key":"1026_CR45","first-page":"1573","volume":"62","author":"RE Ferner","year":"2002","unstructured":"Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62:1573\u20137.","journal-title":"Cancer Res"},{"key":"1026_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdag033","volume":"8","author":"PL Nghiemphu","year":"2026","unstructured":"Nghiemphu PL, Cordova CL, Bowling A, Crites A, Yang X, Dettling T. Adult patient and caregiver perspectives on the impact of NF1-PN: insights from a US qualitative survey. Neuro-oncol Adv. 2026;8:vdag033.","journal-title":"Neuro-oncol Adv"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01026-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01026-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:57:39Z","timestamp":1791449859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01026-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":46,"alternative-id":["1026"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01026-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ayo Adeyemi, Michelle Erdmann, and Theresa Dettling are employees of, and may own stocks in, Alexion, AstraZeneca Rare Disease. Rosalie E. Ferner has acted as medical advisor for AstraZeneca and Alexion, AstraZeneca Rare Disease on neurofibromatosis. Phioanh L. Nghiemphu has received grants paid to their institution from the Children\u2019s Tumor Foundation, ERASCA, SpringWorks Therapeutics, and Recursion; has received consulting fees for participation in advisory boards for Alexion, AstraZeneca Rare Disease, CIRM, and SpringWorks Therapeutics; and has received payment or honoraria for presentations from SpringWorks Therapeutics. Susanna\u00a0Burckhardt was an employee of Alexion, AstraZeneca Rare Disease at the time of study, and may own stocks in Alexion, AstraZeneca Rare Disease. Abby Crites is an employee of IQVIA, a company commissioned to conduct double-blinded market research with HCPs on behalf of Alexion.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles of the Declaration of Helsinki of 1964 and its subsequent amendments, where applicable. Formal approval from an independent ethics committee or institutional review board was not required because the study was non-interventional, non-clinical, and involved only anonymized survey responses, consistent with prevailing regulations and codes of conduct in each jurisdiction.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}